Summary
Veeva Systems opened fiscal 2025 with revenue of $650.3 million in the quarter ended April 30, 2024, up 23.6% from the prior-year quarter. Gross profit rose 32.5% to $476.5 million, and gross margin widened to 73.3% from 68.3%. Operating income climbed 152.2% to $155.2 million, pushing operating margin to 23.9% from 11.7%. Net income rose 22.9% to $161.7 million, and diluted earnings per share rose 21.0% to $0.98.
Those GAAP comparisons need context. Veeva standardized termination for convenience rights in its master subscription agreements starting February 1, 2023, which shifted the timing of revenue for certain customer contracts and held down revenue, operating income and net income in the fiscal 2024 first quarter. The current quarter also carried a litigation settlement accrual. The reported margin expansion therefore looks less like a clean step change in underlying economics.
Non-GAAP results strip out stock-based compensation, amortization of purchased intangibles and that litigation settlement. Non-GAAP operating income was $260.9 million, non-GAAP net income was $247.0 million, and non-GAAP diluted earnings per share was $1.50, with a non-GAAP operating margin of 40.1%. Stock-based compensation of $95.9 million in the quarter keeps the gap between GAAP and non-GAAP profit wide.
Cash generation was the standout. Operating cash flow was $763.5 million, up 50.9% from the prior-year quarter, helped by collections on annual subscription billings, which make the first quarter seasonally the strongest for cash. Management cautioned that operating cash flow will be substantially lower in the remaining quarters of the fiscal year, and that cash income tax payments tied to the capitalization of research and development expenditures are expected to weigh on operating cash flow for the fiscal year ending January 31, 2025. Deferred revenue, current portion, stood at $1.03 billion, up 18.3% year over year. Cash, cash equivalents and short-term investments totaled $4.8 billion at April 30, 2024, with $85 million of that held outside the United States.
Product momentum was broad. Vault CRM became fully available to all new customers in April, and Veeva logged 13 CRM wins in the quarter. Three top 20 biopharmas signed for multiple Development Cloud applications, each including clinical. Compass Patient added a record 21 new brands, including a first seven-figure enterprise-wide win with a top 50 biopharma, and Compass Prescriber and Compass National signed their first customers. Veeva Link crossed the 100-customer mark. Vault Basics launched as a preconfigured entry point with no implementation cost, aimed at emerging biotechs, a nod to the many smaller pre-commercial customers in the R&D base. R&D Solutions supplied about 51% of subscription services revenue in the quarter, and management expects that mix to keep rising.
Guidance covers the fiscal second quarter ending July 31, 2024 and the full fiscal year ending January 31, 2025. For the second quarter, management guided non-GAAP operating income to a range of $265 million to $267 million and non-GAAP diluted earnings per share to $1.53 to $1.54. For the full fiscal year, non-GAAP operating income is guided to about $1,070 million and non-GAAP diluted earnings per share to approximately $6.16. Veeva cannot provide GAAP targets for those profit measures because excluded items such as stock-based compensation are hard to estimate and the effect may be significant.
The risk list is familiar for this franchise. Stated concerns include product performance, security and privacy, competitive factors, customer decisions and priorities, conditions in the life sciences industry, and macroeconomic and geopolitical events such as inflationary pressures, interest rate moves, currency fluctuations, Russia's invasion of Ukraine and the Israel-Hamas conflict. Hiring and retention also matter given a cost base that is largely headcount driven. Results carry foreign exchange exposure across the Euro, Japanese Yen, Canadian Dollar, British Pound Sterling and Chinese Yuan. The tax line swung from a benefit to an expense during the quarter as excess tax benefits from equity compensation shrank, a reminder that part of the earnings history depends on stock plan activity rather than operations alone.
Forecast
Reported figures
GAAP, from SEC filings| Metric | Q1 FY2025 | Q4 FY2024 | QoQ | Q1 FY2024 | YoY |
|---|---|---|---|---|---|
| Revenue | $650.3M | $630.6M | +3.1% | $526.3M | +23.6% |
| Gross profit | $476.5M | $456.7M | +4.3% | $359.7M | +32.5% |
| Gross margin | 73.3% | 72.4% | +0.8 pp | 68.3% | +4.9 pp |
| Research & development | $162.7M | $163.6M | -0.5% | $147.0M | +10.7% |
| Sales & marketing | $97.3M | $99.2M | -1.9% | $88.5M | +9.9% |
| General & administrative | $61.3M | $58.7M | +4.5% | $62.7M | -2.2% |
| Total operating expenses | $321.3M | $321.4M | -0.0% | $298.1M | +7.8% |
| Operating income (loss) | $155.2M | $135.3M | +14.7% | $61.5M | +152.2% |
| Operating margin | 23.9% | 21.4% | +2.4 pp | 11.7% | +12.2 pp |
| Net income (loss) | $161.7M | $147.4M | +9.7% | $131.5M | +22.9% |
| Net margin | 24.9% | 23.4% | +1.5 pp | 25.0% | -0.1 pp |
| Diluted EPS | $0.98 | $0.90 | +$0.08 | $0.81 | +$0.17 |
| Customers | 1,205 | 1,432 | -15.9% | 993 | +21.3% |
Risks
In April 2024, Salesforce, Inc. and IQVIA announced an expanded CRM partnership under which IQVIA will license its CRM software to Salesforce and both parties will jointly market a new life sciences industry-specific CRM solution that will compete with Veeva CRM. This intensifies competition in Veeva's largest product category.
Veeva plans to migrate Veeva CRM customers to Vault CRM because it does not intend to renew its Salesforce agreement when the current term expires on September 1, 2025. The migration may cause business disruptions, lead customers to choose competitors that remain on Salesforce, and is subject to wind-down limits on selling Salesforce-based applications to new customers and on seat expansion.
IQVIA will not consent that customers using its healthcare professional or healthcare organization data may upload such data to Veeva Network, has restricted uploads to Veeva Nitro and other applications, and has stated it will deny all customer requests for new IQVIA data types in Veeva applications. These restrictions have negatively affected sales and customer adoption of Veeva Network and may continue to harm demand.
Top 10 customers accounted for 28% of total revenues in the fiscal year ended January 31, 2024, compared with 29% in the prior fiscal year and 31% in the fiscal year ended January 31, 2022. The loss of one or more key customers, or their failure to renew or expand subscriptions, could slow revenue growth or cause revenues to decline.
Nearly all revenues come from life sciences customers, exposing Veeva to drug pricing reforms such as the Inflation Reduction Act, industry consolidation, reduced funding for early-stage life sciences companies since 2022, and high interest rates. These factors could reduce customer spending, sales representative headcount, and demand for Veeva solutions.
Commercial Solutions represented approximately 49% of subscription services revenues and 48% of total revenues for the three months ended April 30, 2024, and Veeva CRM has achieved substantial penetration among pharmaceutical and biotechnology companies. In recent years, life sciences companies reduced sales representatives due to an increased preference for digitally-enabled sales channels, which negatively impacted sales of Veeva CRM and certain other Commercial Solutions.
The sales cycle for a new customer may span 12 months or longer. Veeva has recently experienced increased scrutiny for certain potential projects, particularly for professional services offerings, which may continue for the foreseeable future and harm operating results and growth if sales cycles lengthen.
Washington's My Health My Data Act became effective on March 21, 2024, and may curtail Veeva's ability to use data of Washington consumers, which could limit the accuracy of and reduce demand for Veeva Crossix products. Compliance with evolving privacy laws such as the EU AI Act may require product changes and increase costs.
In 2023, certain Veeva CRM customers in China were required to request approval from the Cyberspace Administration of China to transfer data outside China and had their requests denied. Customers may implement a competitor's CRM solution that does not require cross-border data transfers, and approximately 2% of total revenue is attributable to China.
Veeva has been defending against trade secret misappropriation assertions by IQVIA since January 2017 and remains in active litigation with IQVIA. General and administrative expenses for the three months ended April 30, 2024 included a litigation settlement accrual, and litigation could result in significant damages, expenses, and management distraction.
The effective tax rate increased to 21.9% for the three months ended April 30, 2024 from (43.3)% for the prior-year period, primarily due to the reduced benefit from excess tax benefits related to equity compensation. Cash payments for income taxes under the Tax Cuts and Jobs Act of 2017 are expected to reduce operating cash flows in the fiscal year ending January 31, 2025.
SaaS KPIs
All quarters →Total Customers
Non-GAAP Operating Margin
Commercial Solutions customers
R&D Solutions customers
Non-GAAP Operating Income
Summary, forecast, risks and KPIs are extracted from VEEVA SYSTEMS INC's SEC filings for Q1 FY2025 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 6, 2026.